The post Crypto market sentiment rebounds to neutral as trading volumes remain muted appeared on BitcoinEthereumNews.com. Crypto market sentiment has rebounded The post Crypto market sentiment rebounds to neutral as trading volumes remain muted appeared on BitcoinEthereumNews.com. Crypto market sentiment has rebounded

Crypto market sentiment rebounds to neutral as trading volumes remain muted

Crypto market sentiment has rebounded to neutral territory after spending much of late 2025 in fear, according to data from the Crypto Fear and Greed Index. 

The recovery in sentiment comes as digital asset prices stabilise across major tokens. However, spot trading activity suggests market participation remains restrained.

At the time of writing, the Fear and Greed Index sits at 54 [Neutral], up from 43 last week and 24 one month ago. This marks a steady improvement in risk appetite following the sharp drawdown seen toward the end of last year. 

While the shift reflects improving confidence, accompanying volume data indicates that traders are still approaching the market cautiously.

Crypto market sentiment improves after late-2025 fear phase

The recent crypto market rebound follows a period of pronounced risk aversion in November 2025, when the index briefly fell to Extreme Fear [10] — its lowest reading of the year. 

That decline coincided with broader market weakness, declining liquidity, and falling spot volumes across centralised exchanges.

Source: CoinMarketCap

Since then, sentiment has gradually recovered alongside stabilising prices across large-cap assets. However, the index’s return to neutral suggests uncertainty remains, with neither fear nor greed dominating market psychology.

Crypto market Spot trading volumes remain below prior highs

Despite the improvement in sentiment, spot trading volumes in the crypto market have yet to show a sustained recovery. 

CoinMarketCap data shows that daily spot volumes remain well below mid-2025 peaks, when activity regularly exceeded $600 billion to $900 billion during periods of heightened volatility.

Recent readings place daily spot volume closer to $400 billion, reflecting thinner liquidity and reduced speculative participation. 

Source: CoinMarketCap

Historically, sustained bullish momentum has tended to coincide with expanding spot volumes — a condition that has yet to materialise fully.

Bitcoin provides price stability, not market leadership

Bitcoin’s price action continues to offer a reference point for broader crypto market conditions rather than acting as a primary catalyst. 

The asset has rebounded from late-2025 lows and is trading higher on the year, but without the explosive volume expansion typically associated with major trend reversals.

Notably, Bitcoin’s recent price strength has occurred alongside relatively flat spot volume and moderate accumulation signals, suggesting that current moves are being driven more by selective positioning than widespread risk-on behaviour.

Crypto market recovery remains measured

The data paints a picture of a crypto market in transition. Sentiment has improved, price stability has returned, and downside volatility has eased. 

Yet the lack of strong volume confirmation suggests traders remain selective, with capital deployment still cautious rather than aggressive.

Until spot activity expands meaningfully, the current sentiment recovery appears more reflective of stabilisation than a full return to speculative momentum.


Final Thoughts

  • Crypto market sentiment has recovered to neutral levels after a prolonged period of fear, reflecting improving confidence across digital assets.
  • However, persistently subdued spot trading volumes suggest participation remains cautious, indicating the recovery is stabilising rather than speculative in nature.

Next: Why is XMR up today? Monero rallies as Zcash loses trust

Source: https://ambcrypto.com/crypto-market-sentiment-rebounds-to-neutral-as-trading-volumes-remain-muted/

Market Opportunity
Index Cooperative Logo
Index Cooperative Price(INDEX)
$0.5337
$0.5337$0.5337
+5.22%
USD
Index Cooperative (INDEX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26